A Precision Oncology Approach Calls for Regular ESR1 Monitoring
Emerging liquid biopsy techniques enable sensitive, routine monitoring of ESR1 mutations in metastatic HR+ breast cancer.
Read MorePosted by Chris Wolski | Jun 17, 2025 | Breast |
Emerging liquid biopsy techniques enable sensitive, routine monitoring of ESR1 mutations in metastatic HR+ breast cancer.
Read MorePosted by Chris Wolski | Jun 12, 2025 | Digital Pathology |
Laboratory leaders see digital pathology and AI as essential for driving precision medicine and long-term transformation in the industry.
Read MorePosted by Chris Wolski | Jun 11, 2025 | Cancer |
Florida Cancer Specialists & Research Institute now offers liquid biopsy, a minimally invasive blood test that enhances cancer diagnosis.
Read MorePosted by Chris Wolski | Jun 10, 2025 | Molecular Diagnostics |
Rutgers and Yale engineers have developed a portable device that rapidly detects rare genetic mutations from a single drop of blood.
Read MorePosted by Chris Wolski | Jun 3, 2025 | Compliance |
A federal court ruled in favor of AMP, striking down the FDA’s attempt to regulate laboratory-developed tests (LDTs) as medical devices.
Read More